Prostate Cancer Studies
STUDIES CURRENTLY RECRUITING
MDV3100-14
A multinational, Phase 3, Randomized, Double- Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastic Castration-Resistant
Prostate Cancer Recruiting
Dendreon P12-2
A Randomized, Open-Label, Phase 2 Study of Sipuleucel-T with Concurrent versus sequential Administration of Enzalutamidein Men with Metastatic castrate resistant prostate cancer
ARN-509 - SPARTAN Study
Phase III study comparing ARN-509 (pill) to placebo for patients with non-metastatic prostate cancer Recruiting
Galeterone - TOK ARMOR 2 study
2 part Phase II study of galeterone -TOK (pill) for patients with metastatic prostate cancer pre and post-chemotherapyRecruiting
OGX-011 (Custersin) + Jevtana
Phase III study of Jevtana +/- Custersin second line chemotherapy for patients with metastatic prostate cancer Recruiting
Prolia (denosunab)
Phase III study to evaluate Prolia for patients with prostate cancer taking hormones
Recruiting
Prostvac (vaccine)
Phase III study vaccination study for patients with advanced prostate cancer who have not yet received treatment with chemotherapy and have no symptoms or minimal symptoms Recruiting
Provenge PROCEED study (vaccine)
Registry study to collect long term safety data for patients receiving Provenge vaccine
Recruiting
Provenge PROCEED sub - study
Immune response study (additional blood samples collected) for patients participating in PROCEED study Recruiting
PSMA ADC
Phase II study of PSMA ADC (target chemotherapy) in patients with metastatic prostate cancer who have failed chemotherapy Recruiting
VT-464-CL-001 (testosterone inhibitor)
Phase I/II study to evaluate the safety of the study drug VT-464 (pill) and how it affects patients with prostate cancer Recruiting
XL184 (Cabozantinib)
Phase II study comparing XL184 (Cabozantinib) (pill) vs. Prednisone only for patients who have failed Zytiga (abiraterone) or Xtandi (MDV3100) Recruiting
Xtandi (MDV 3100) - STRIVE
Phase II study comparing Xtandi to standard of care Casodex for patients with Prostate cancer Recruiting
Androgen deprivation vs. Radiotherapy
Phase III study comparing androgen deprivation prior with pelvic lymph node dissection vs. radiotherapy only Recruiting
Taxotere
Phase III study to evaluate the addition of Taxotere prior to surgery to improve outcome for patients with newly diagnosed high risk prostate cancer Recruiting
Taxotere +/- GM-CSF
Phase II study of intermittent Taxotere vs. intermittent Taxotere with GM-CSF
STUDIES ACTIVE, CLOSED TO ENROLLMENT
Zytiga – Rising PSA IMAAGEN study
Phase III study of Zytiga plus prednisone for patients with rising PSA prostate cancer who are receiving hormone therapy Closed to enrollment – active follow-up
TAK-700 (Orteronel) Pre-chemotherapy
Phase III study of TAK-700 plus prednisone for patients with advanced prostate cancer who have not yet received treatment with chemotherapy Closed to enrollment –
active follow-up
TAK-700 (Orteronel) Post-chemotherapy
Phase III study of TAK-700 plus prednisone for patients with advanced prostate cancer previously treated with chemotherapy Closed to enrollment – active follow-up
TAK-700 (Orteronel)
Phase II Open-label study of oral TAK-700 plus prednisone, evaluating the effects on the heart for patients with advanced prostate cancer Closed to enrollment – active
follow-up
TAK-700 (Orteronel)
Phase II Open-label study of oral TAK-700 plus prednisone, evaluating dosing options for patients with advanced prostate cancer Closed to enrollment – active
follow-up
Zytiga Cougar 302 study
Phase III study of oral Zytiga™ plus prednisone for patients with advanced prostate cancer who have not yet received treatment with chemotherapy Closed to
enrollment – active follow-up
Zytiga + Provenge
Open-label Phase II study of Provenge with concurrent or sequential Zytiga.
Closed to enrollment – active follow-up
PRIOR STUDIES - CLOSED
Genentec GDC + Zytiga
Phase II study of GDC + Zytiga, versusZytiga alone for patients with advanced prostate cancer previously treated with chemotherapy Closed
Zytiga Cougar 301 study
Phase III study of oral Zytiga plus prednisone for patients with advanced prostate cancer who have already received chemotherapy Closed
Zytiga EAP study
EAP oral Zytiga plus prednisone for patients with advanced prostate cancer who have already received chemotherapy Closed
MDV3100 EAP study
EAP oral MDV3100 for patients with advanced prostate cancer who have already received chemotherapy Closed
TroVax
Phase II study to evaluate the addition of TroVax vaccination to standard Taxotere chemotherapy for patients with advanced prostate cancer Closed
OGX-011 (Custersin)
Phase III study of OGX-011 (Custersin) added to Taxotere for second line treatment evaluation of pain palliation Closed
Eligard +/- Taxotere - Rising PSA
A Phase III study Eligard +/- Taxotere for patients with Rising PSA Closed
Bladder Cancer Studies
DN24-02 (vaccination)
DN24-02 (vaccination) added to standard of care treatment for patients with HER2+ bladder cancer Recruiting
Avastin added to Gemcitabine + Cisplatin chemotherapy
Phase II study comparing Avastin, Gemcitabine + Cisplatin chemotherapy to Gemcitabine + Cisplatin alone Recruiting
Intravesical chemotherapy with Gemcitabine, Mitomycin
Taxotere
Treatment for superficial bladder cancer in which chemotherapy drugs are infused directly into the bladder through a catheter (intravesical) Recruiting
Bladder preservation
Bladder preservation with chemotherapy prior to surgery, TURBT (transurethral resection of bladder tumor), concurrent radiation + chemotherapy Recruiting
STUDIES ACTIVE, CLOSED TO ENROLLMENT
OGX-427-02 added to Gemcitabine + Cisplatin chemotherapy
Phase II study of Gemcitabine + Cisplatin chemotherapy with study drug OGX-427-02 for advanced bladder cancer Closed to enrollment – active follow-up
Kidney Cancer Studies
AVE0005 (veg trap)
Phase II study to determine the effects of two different doses of AVE0005 (veg trap) in patients with advanced kidney cancer Recruiting
Sutent
Treatment with Sutent (pill) prior to surgery/cryosurgery Recruiting
AGS-003-007
An International Phase 3 Randomized Trial of Autologous Dendritic Cell
Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT) Recruiting
